• Explore /
  • Poster
  • / A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.

A phase II study of MT-3724, a novel CD20-targeting engineered toxin body, to evaluate safety, pharmacodynamics, and efficacy in subjects with relapsed or refractory diffuse large B-cell lymphoma.

Abstract Video & Slides Poster

Authors

Adolfo Diaz Duque

Adolfo Enrique Diaz Duque

University of Texas Health at San Antonio, San Antonio, TX

Adolfo Enrique Diaz Duque , Tetiana Perekhrestenko , Vasile Musteata , Mamia Zodelava , Troy H. Guthrie Jr., Thomas Strack , Christine Burnett , Sarah Wilson , Roger J. Waltzman , Tara D. Baetz , Daniel O. Persky

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02361346

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS8074)

DOI

10.1200/JCO.2020.38.15_suppl.TPS8074

Abstract #

TPS8074

Poster Bd #

407

Abstract Disclosures

Similar Posters

First Author: Michelle A. Fanale

First Author: Martin H. Dreyling

First Author: Philippe Armand

First Author: Andrew David Zelenetz